2m 2m 2m 2m 2m 2m 2m
THERAPEUTICSMD (TXMD)
NASDAQ
$2.00+$0.03 (+1.68%)
Price as of Jun 03, 2026 7:03 PM EDT- $24.8MMarket Cap
- 88.89%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
THERAPEUTICSMD (TXMD)
$2.00+$0.03 (+1.68%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 3.0M +71.61% | 1.8M +35.25% | 1.3M -98.14% | 70.0M -19.54% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | 1.4M -92.58% | |
Gross Profit | 3.0M +71.61% | 1.8M +35.25% | 1.3M -98.10% | 68.6M +0.67% | |
Sales and Marketing Expense | N/A N/A | 4.7M -64.06% | 13.2M 0.00% | 13.2M -87.80% | |
Research and Development Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Depreciation and Amortization Expense | 384,000 -24.56% | 509,000 -44.79% | 922,000 -22.72% | 1.2M -70.85% | |
Total Operating Expenses | 7.4M +13.66% | 6.5M -33.63% | 9.8M -85.42% | 67.4M -67.59% | |
Operating Profit | -4.4M -7.77% | -4.8M -44.15% | -8.5M -815.62% | 1.2M +100.85% | |
Interest Income | 142,000 -2.00% | 144,900 N/A | N/A N/A | N/A N/A | |
Interest Expense | -8,000 -15.79% | -9,500 -96.83% | -300,000 -99.17% | -36.1M +9.56% | |
Interest Income and Expense and Net | 134,000 -1.03% | 135,400 +145.13% | -300,000 -99.17% | -36.1M +10.48% | |
Total Nonoperating Income and Expense | 3.7M +54.61% | 2.4M +209.48% | 781,000 +767.52% | -117,000 -99.64% | |
Income before Taxes | -653,000 -72.13% | -2.3M -69.74% | -7.7M -820.86% | 1.1M +100.62% | |
Income Taxes | N/A N/A | -31,000 -27.91% | -43,000 N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -569,000 -73.91% | -2.2M -78.78% | -10.3M -109.18% | 112.0M +164.96% | |
Net Income from Continuing Operations Applicable to Common | -653,000 -71.76% | -2.3M -69.97% | -7.7M -816.85% | 1.1M +100.62% | |
Basic EPS and Net Income | -0.05 -73.68% | -0.19 -80.61% | -0.98 -107.90% | 12.41 +2,986.05% | |
Diluted EPS and Net Income | -0.05 -73.68% | -0.19 -80.61% | -0.98 -108.19% | 11.96 +2,881.40% | |
Basic Weighted Average Shares | 11.6M +100,220.85% | 11,532 -99.89% | 10.4M +15.65% | 9.0M -97.73% | |
Diluted Weighted Average Shares | 11.6M +100,220.85% | 11,532 -99.89% | 10.4M +11.48% | 9.4M -97.65% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 7.5M +47.91% | 5.1M +16.92% | 4.3M -88.63% | 38.1M -41.55% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 7.5M +47.91% | 5.1M +16.92% | 4.3M -88.63% | 38.1M -41.55% | |
Total Current Assets | 14.4M +17.83% | 12.3M +3.93% | 11.8M -78.69% | 55.4M -53.67% | |
Accumulated Depreciation | N/A N/A | N/A N/A | 2.5M +3.15% | 2.4M -2.90% | |
Property and Plant and Equipment and Net | N/A N/A | N/A N/A | N/A N/A | 78,000 -93.49% | |
Total Long-Term Assets | 444,000 +241.54% | 130,000 +124.14% | 58,000 -77.08% | 253,000 0.00% | |
Total Assets | 37.7M -3.00% | 38.8M -10.36% | 43.3M -52.12% | 90.5M -46.62% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | 188.3M 0.00% | |
Total Current Liabilities | 4.8M -7.38% | 5.2M -24.63% | 6.9M -85.37% | 46.8M -81.48% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | 188.3M N/A | |
Total Long-Term Liabilities | 873,000 +17.34% | 744,000 +16.98% | 636,000 -42.55% | 1.1M -48.25% | |
Total Liabilities | 10.8M -5.87% | 11.5M -18.33% | 14.0M -74.65% | 55.3M -78.98% | |
Retained Earnings | -952.4M +0.06% | -951.8M +0.23% | -949.6M +1.09% | -939.4M -10.65% | |
Total Stockholders Equity | 26.9M -1.80% | 27.4M -6.55% | 29.3M -16.66% | 35.1M +137.54% | |
Total Shares Outstanding | 11.6M +0.36% | 11.5M 0.00% | 11.5M +21.42% | 9.5M -97.79% | |
Cash Flow | |||||
Cash from Operating Activities | 2.4M +231.15% | 732,000 +101.52% | -48.1M +1,080.51% | -4.1M -97.14% | |
Capital Expenditures | N/A N/A | N/A N/A | N/A N/A | 34,000 0.00% | |
Cash from Investing Activities | N/A N/A | N/A N/A | 0 -100.00% | 223.5M +10,153.04% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | N/A N/A | N/A N/A | 3.2M +101.34% | -235.2M -281.55% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | 98.00% +25.11% | |
Operating Margin | -145.27% -46.26% | -270.30% -58.71% | -654.61% -38,554.34% | 1.70% +101.06% | |
Return on Assets | -1.49% -71.98% | -5.31% -65.44% | -15.37% -117.83% | 86.17% +187.74% | |
Return on Equity | -2.10% -72.75% | -7.70% -75.87% | -31.90% -91.67% | -383.04% -341.74% | |
Revenue Growth | 71.61% +103.12% | 35.25% +135.92% | -98.14% +402.31% | -19.54% -157.41% | |
Current Ratio | 3.02 +27.21% | 2.37 +37.88% | 1.72 +45.64% | 1.18 +150.15% | |
Cash Ratio | 1.56 +59.69% | 0.98 +55.12% | 0.63 -22.32% | 0.81 +215.61% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | 10.71 +632.79% | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | 4.16 +274.71% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow